Zacks: Analysts Expect Insulet Co. (PODD) Will Post Quarterly Sales of $125.25 Million

Wall Street analysts expect that Insulet Co. (NASDAQ:PODD) will report $125.25 million in sales for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have made estimates for Insulet’s earnings, with the highest sales estimate coming in at $127.49 million and the lowest estimate coming in at $124.20 million. Insulet reported sales of $103.58 million in the same quarter last year, which indicates a positive year over year growth rate of 20.9%. The business is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, February 21st.

According to Zacks, analysts expect that Insulet will report full-year sales of $125.25 million for the current fiscal year, with estimates ranging from $457.40 million to $460.79 million. For the next financial year, analysts forecast that the firm will report sales of $556.15 million per share, with estimates ranging from $510.43 million to $588.51 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Insulet.

Several equities research analysts recently weighed in on the company. Zacks Investment Research raised Insulet from a “sell” rating to a “hold” rating in a report on Thursday, February 1st. BidaskClub raised Insulet from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Raymond James Financial upgraded Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research note on Monday, January 8th. UBS Group upgraded Insulet from a “market perform” rating to an “outperform” rating in a research note on Monday, January 8th. Finally, Barclays restated a “buy” rating and issued a $78.00 target price on shares of Insulet in a research note on Wednesday, December 13th. Eight investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $62.53.

Shares of Insulet (NASDAQ PODD) opened at $72.46 on Wednesday. Insulet has a twelve month low of $38.43 and a twelve month high of $78.65. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42.

Several institutional investors and hedge funds have recently modified their holdings of the company. Frontier Capital Management Co. LLC boosted its position in shares of Insulet by 42.4% during the 4th quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock valued at $144,633,000 after acquiring an additional 624,465 shares during the last quarter. State Street Corp boosted its position in shares of Insulet by 7.7% during the 2nd quarter. State Street Corp now owns 1,189,155 shares of the medical instruments supplier’s stock valued at $61,014,000 after acquiring an additional 85,280 shares during the last quarter. Lord Abbett & CO. LLC boosted its position in shares of Insulet by 29.6% during the 2nd quarter. Lord Abbett & CO. LLC now owns 838,302 shares of the medical instruments supplier’s stock valued at $43,013,000 after acquiring an additional 191,217 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Insulet by 328.2% during the 4th quarter. Renaissance Technologies LLC now owns 661,200 shares of the medical instruments supplier’s stock valued at $45,623,000 after acquiring an additional 506,800 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Insulet by 104.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 611,595 shares of the medical instruments supplier’s stock valued at $34,035,000 after acquiring an additional 313,093 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://stocknewstimes.com/2018/02/21/zacks-analysts-expect-insulet-co-podd-will-post-quarterly-sales-of-125-25-million.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply